NCT06126276 2026-03-18
Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial)
National Cancer Institute (NCI)
Phase 2 Recruiting
Clinical Trials
56 trialsNCT06581432 2026-03-17
Beamion PANTUMOR-1: A Study to Test Whether Zongertinib Helps People With Advanced Cancers With HER2 Alterations
Boehringer Ingelheim
Phase 2 Recruiting
NCT06840834 2026-03-16
Bi-MAPS
Intergroupe Francophone de Cancerologie Thoracique
Phase 2 Recruiting
NCT07018622 2026-03-11
DAPA-ARMOR
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Phase 2 Recruiting
NCT07111546 2026-03-11
A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 02(BTC&HCC)]
Nanjing Leads Biolabs Co.,Ltd
Phase 2 Recruiting
NCT07196644 2026-03-11
A Study to Assess Adverse Events and Change in Disease Activity in Participants 12 Years of Age or Older With Locally Advanced or Metastatic Solid Tumors That Harbor MET Amplification Receiving Intravenously Infused Telisotuzumab Adizutecan
AbbVie
Phase 2 Recruiting
NCT07331155 2026-03-09
A Phase II Clinical Study of LBL-024 Combination Therapy in Patients With Advanced Solid Tumour[Substudy 03(ESCC)]
Nanjing Leads Biolabs Co.,Ltd
Phase 2 Recruiting
NCT04589845 2026-03-06
Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study
Hoffmann-La Roche
Phase 2 Recruiting
NCT07246863 2026-03-04
Trial Investigating Visugromab and Nivolumab With or Without Docetaxel in 2L Treatment of Participants With Metastatic NSCLC
CatalYm GmbH
Phase 2 Recruiting
NCT07028281 2026-03-03
A Trial of SHR-4849 Combined With Other Antitumor Drugs in Patients With Malignant Solid Tumors
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 2 Recruiting
NCT06410209 2026-02-27
A Culturally-Tailored Mobile Health and Social Media Physical Activity Intervention for Improving Physical Activity in Hispanic or Latino/Latina Adolescent and Young Adult Childhood Cancer Survivors, Walking Juntos Study
Children's Oncology Group
Phase 2 Recruiting
NCT06629584 2026-02-17
Phase II Study of Asciminib for Second-line Treatment of Chronic Phase Chronic Myeloid Leukemia
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT06651593 2026-02-17
Phase II Biomarker Study of SAR444881 in Combination With Cemiplimab in Solid Tumors
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT06783647 2026-02-12
A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 01(NSCLC)]
Nanjing Leads Biolabs Co.,Ltd
Phase 2 Recruiting
NCT06534190 2026-02-09
CD8 PET Imaging in Metastatic Solid Tumours
University Medical Center Groningen
Phase 2 Recruiting
NCT06470971 2026-01-20
Siltuximab for the Prevention of Severe Immune-Related Adverse Events During Immune Checkpoint Inhibitor Rechallenge in Patients With Advanced Cancer, CIRES Trial
Ohio State University Comprehensive Cancer Center
Phase 2 Recruiting
NCT07268040 2026-01-12
A Trial of SHR-7787 Injection Combined With Other Anti-tumor Drugs in Patients With Malignant Solid Tumors
Shanghai Hengrui Pharmaceutical Co., Ltd.
Phase 2 Recruiting
NCT07321574 2026-01-07
ABP1011T-03
Shanghai AB PharmaTech Ltd.
Phase 2 Recruiting
NCT07028268 2025-12-31
A Trial of SHR-2017 Injection in Patients With Bone Metastases From Solid Tumors
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 2 Recruiting
NCT06376292 2025-12-30
A Prospective Single Arm Phase II Exploratory Study on the Combination of Whole Brain Radiotherapy, Thiotepa Intrathecal Injection and Systemic Treatment of Primary Diseases in the Treatment of Solid Tumor Leptomeningeal Metastasis
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2 Recruiting
NCT07003321 2025-12-18
A Trial of HRS-4508 in Subjects With Locally Advanced or Metastatic Non-small Cell Lung Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 2 Recruiting
NCT03736889 2025-12-17
Tislelizumab (Anti-Programmed Cell Death Protein-1 (PD-1) Antibody) in MSI-H or dMMR Solid Tumors
BeOne Medicines
Phase 2 Recruiting
NCT06383884 2025-12-15
Patritumab Deruxtecan in Patients With Solid Tumor Harboring an NRG1 Fusion
Samsung Medical Center
Phase 2 Recruiting
NCT07264803 2025-12-04
PDTF
Qilu Hospital of Shandong University
Phase 2 Recruiting
NCT05730816 2025-11-21
MAGIC-AKI
Brigham and Women's Hospital
Phase 2 Recruiting
NCT07032077 2025-11-20
A Phase II Clinical Trial on the Safety, Tolerability, and Efficacy of HRS-7058 Combined Anti-tumor Drugs in Subjects With Solid Tumors.
Shandong Suncadia Medicine Co., Ltd.
Phase 2 Recruiting
NCT06503146 2025-11-12
18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection
National Institutes of Health Clinical Center (CC)
Phase 2 Recruiting
NCT03007030 2025-11-10
Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT04400539 2025-09-25
IMPALA
University Hospital, Lille
Phase 2 Recruiting
NCT06947291 2025-09-08
Safety and Efficacy of Glumetinib Combined With Docetaxel for Injection (Albumin-bound) in Patients With Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma and Other Solid Tumors
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase 2 Recruiting
NCT06250036 2025-08-21
ZODIAC
Royal Marsden NHS Foundation Trust
Phase 2 Recruiting
NCT07107633 2025-08-06
A Phase II Clinical Study to Evaluate the Efficacy and Safety of Technetium [99mtc]-H7ND Injection in the Diagnosis of Peritoneal Metastasis of Gastrointestinal Malignant Tumor.
Jiaxing Pharmadax Genesis Pharmaceutical Technology Co.,Ltd.
Phase 2 Recruiting
NCT06543056 2025-07-30
A Study of ES014 in Subjects With Advanced Solid Tumors
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Recruiting
NCT06057935 2025-07-22
A Study of Additional Chemotherapy After Surgery for People With Malignant Peritoneal Mesothelioma
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT04040205 2025-07-20
Abemaciclib for Bone and Soft Tissue Sarcoma With Cyclin-Dependent Kinase (CDK) Pathway Alteration
Medical College of Wisconsin
Phase 2 Recruiting
NCT03935893 2025-07-10
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers
University of Pittsburgh
Phase 2 Recruiting
NCT06790082 2025-07-03
FAPI-PM
Aalborg University Hospital
Phase 2 Recruiting
NCT07046650 2025-07-01
Multi-cohort, Single-arm, Phase II Study of the Efficacy and Side Effects of Cisplatin Plus Gemcitabine in the Treatment of PD1 Failure or Intensive Treatment of Some Rare Tumors
Fudan University
Phase 2 Recruiting
NCT06365840 2025-06-18
TMB-H
ImmuneOncia Therapeutics Inc.
Phase 2 Recruiting
NCT05188859 2025-05-31
First Line Sintilimab Combined With Anlotinib and Platinum Doublet Chemotherapy in Malignant Pleural Mesothelioma
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Recruiting
NCT06318286 2025-05-25
PENINSULA
Hyogo Medical University
Phase 2 Recruiting
NCT05541822 2025-05-22
To Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetic Profile of ABN401 in Patients With Advanced Solid Tumors Harboring c-MET Dysregulation
Abion Inc
Phase 2 Recruiting
NCT04515836 2025-05-06
Olaparib in Patients With HRD Malignant Mesothelioma
University of Chicago
Phase 2 Recruiting
NCT06895928 2025-04-22
A Trial of SHR-A2102 With Other Antitumor Therapies in Advanced Solid Tumors
Shanghai Hengrui Pharmaceutical Co., Ltd.
Phase 2 Recruiting
NCT04775485 2025-04-10
FIREFLY-1
Day One Biopharmaceuticals, Inc.
Phase 2 Recruiting
NCT06679634 2025-04-03
Retinoblastoma Phase II Expanded Access Clinical Trial
Targeted Therapy Technologies, LLC
Phase 2 Recruiting
NCT06032845 2025-02-27
CASTLE-11
Fudan University
Phase 2 Recruiting
NCT06527300 2025-01-24
A Multicenter, Open-label, Single-arm, Phase II Study of NHWD-870 HCl in Adults and Adolescents with Advanced NUT Cancer
Zhejiang Wenda Pharma Technology LTD.
Phase 2 Recruiting
NCT06739395 2024-12-18
Precision Medicine Trial Based on Molecular Matching Therapy for Patients With Standard Treatment Exhaustion
Tianjin Medical University Second Hospital
Phase 2 Recruiting
NCT06117540 2024-11-19
A Study of WX390 in Patients With Advanced Solid Tumors
Shanghai Jiatan Pharmatech Co., Ltd
Phase 2 Recruiting